BCRX: the cash flow

Total revenues

-

156,413

729,303

-

Cost of product sales

-

5,377

14,507

-

Acquired in-process research and development

-

697,761

-

Research and development (excluding stock-based compensation)-Navenibart

-

9,741

-

Research and development (excluding stock-based compensation)-Berotralstat

-

4,323

-

Research and development (excluding stock-based compensation)-BCX17725

-

1,907

9,996

-

Research and development (excluding stock-based compensation)-Berotralstat

-

1,796

-

Research and development (excluding stock-based compensation)-Avoralstat

-

893

9,497

-

Research and development (excluding stock-based compensation)-Factor DProgram

-

-1,033

-

Research and development (excluding stock-based compensation)-STAR0310

-

683

-

Research and development (excluding stock-based compensation)-Research Discovery And Preclinical Programs

-

3,970

17,677

-

Research and development (excluding stock-based compensation)-Compensation And Related Personnel Costs

-

27,091

51,576

-

Research and development (excluding stock-based compensation)-Other Expenses1

-

7,419

27,958

-

Sales and marketing (excluding stock-based compensation)

-

42,953

94,616

-

General and administrative (excluding stock-based compensation)

-

42,393

116,006

-

Stock-based compensation

-

16,027

85,066

-

Interest income

-

2,256

10,668

-

Interest expense

-

19,779

55,378

-

Foreign currency losses (gains), net

-

-225

-152

-

Loss on extinguishment of debt

-

-17,332

-

Other expense, net

-

-1,462

12,090

-

Income tax expense

-

1,004

2,804

-

Net (loss) income

-

-721,812

263,829

-

Depreciation

-

461

-

Acquired in-process research and development

-

697,761

-

Depreciation and amortization

-

1,058

-

Amortization of assembled workforce

-

600

-

Inventory obsolescence

-

74

776

-

Stock-based compensation expense

-

16,027

63,698

-

Equity modification associated with sale of biocryst ireland

-

17,548

-

Mark-to-market adjustment on share-based liability

-

-2,807

4,313

-

Payment of pharmakon pik interest

-

23,704

-

Non-cash interest expense on royalty financing obligations

-

13,294

53,163

-

Non-cash interest expense on secured term loan and amortization of debt issuance costs

-

-12,671

-

Amortization of debt issuance costs on term loans

-

149

-

Amortization of premium (discount) on investments, net

-

251

-2,948

-

Loss on extinguishment of debt

-

-17,332

-

Loss on impairment

-

0

-

Gain on sale of non-financial asset

-

550

-

Gain on sale of biocryst ireland

-

3,566

-

Increase in receivables

-

474

22,819

-

Increase in inventory

-

4,847

769

-

Decrease (increase) in prepaid expenses and other assets

-

-3,532

7,695

-

Decrease in royalty financing obligations

-

-8,470

68,428

-

Decrease in accounts payable and accrued expenses

-

-60,395

104,945

-

Decrease in deferred revenue

-

-749

0

-

Net cash used in operating activities

-

-61,791

291,960

-

Acquisitions of property and equipment

-

403

2,325

-

Purchases of investments

-

0

213,478

-

Sales and maturities of investments

-

221,235

180,647

-

Sale of non-financial asset

-

550

-

Proceeds from sale of biocryst ireland, net of cash divested

-

-6,183

-

Acquisition of astria therapeutics, inc., net of cash acquired

-

489,480

-

Net cash (used in) provided by investing activities

-

-268,648

-83,488

-

Net proceeds from common stock issued under stock-based compensation plans

-

19,479

6,725

-

Withholding taxes paid on stock-based awards

-

1,187

7,496

-

Common stock issued to directors in lieu of cash retainer

-

33

59

-

Proceeds from issuance of long-term debt

-

400,000

0

-

Repayment of principal on term loans

-

300,000

-

Prepayment premium and fees on term loans

-

9,886

-

Payment of debt issuance costs on term loan

-

4,952

0

-

Principal payments on royalty financing obligations

-

476

22,883

-

Payment of royalty release fees

-

15,500

-

Principal payments on finance lease liabilities

-

345

1,473

-

Net cash provided by financing activities

-

412,552

-217,960

-

Increase (decrease) in cash, cash equivalents and restricted cash, including cash classified within current assets held for sale

70,473

-

-4,086

Effect of exchange rates on cash, cash equivalents and restricted cash

-

-72

-

Less net increase in cash and cash equivalents classified within current assets held for sale

-14,840

-

-218

Net increase (decrease) in cash, cash equivalents, and restricted cash

-16,994

82,041

-15,544

-

Beginning of period

173,378

91,337

106,323

-

End of period

156,384

-

Cash and cash equivalents

154,972

-

Restricted cash

479

-

Restricted cash in other assets

933

-

Net decrease in cash, and cash equivalents, and restricted cash

-

-3,868

Total cash, cash equivalents and restricted cash

156,384

173,378

91,337

-

MyFinsight

Cash Flow Overview

Time Plot

Cash Flow

Cash Flow Overview

Time Plot

Cash Flow